Sequent Scientific Limited has informed the Exchange about Transcript
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SeQuent Scientific reported Q1 FY26 revenue of INR 4,414 million, up 13.1% year-on-year, with adjusted EBITDA of INR 602 million at a 13.6% margin and profit after tax jumping 93.7% YoY to INR 176 million. Formulation business (75% of revenue) grew 13% YoY, while API business touched INR 100 crore mark for the first time, growing 14% YoY. Gross margin improved 180 basis points YoY to 46.9%. The proposed merger with Viyash Life Sciences has received CCI and stock exchange approvals, with NCLT shareholder and creditor meeting scheduled for August 30, 2025. Viyash standalone posted INR 353 crore revenue and INR 68 crore EBITDA at 19.5% margins. Combined entity revenue grew 8.7% YoY with EBITDA up 21% and net debt to EBITDA at 0.6x. Management guided gross margins toward 50%, mid-teens EBITDA for SeQuent, high-teens for Viyash, and combined margins of around 20% by 2027.
Strong quarter with broad-based growth and margin expansion signals business is in acceleration phase post-restructuring. Merger clearance progress reduces execution risk and opens synergy realization. Positive read-through for shareholders; watch debt restructuring post-merger as a near-term catalyst.